Seizure disorders:
Indications for: ZTALMY
Seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).
Adults and Children:
<2yrs: not established. Take with food. Give 3 times daily in equally divided doses using oral syringe. ≥2yrs (≤28kg; dose based on body wt.): initially 18mg/kg/day for Days 1–7; 33mg/kg/day for Days 8–14; 48mg/kg/day for Days 15–21; then 63mg/kg/day thereafter; (>28kg): initially 450mg/day for Days 1–7; 900mg/day for Days 8–14; 1350mg/day for Days 15–21; then 1800mg/day thereafter.
ZTALMY Warnings/Precautions:
Monitor for somnolence and sedation. Monitor for depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior. Avoid abrupt cessation. Withdraw gradually. Hepatic impairment: monitor; may need lower dose. Pregnancy. Nursing mothers.
ZTALMY Classification:
GABAA receptor modulator.
ZTALMY Interactions:
Avoid concomitant strong or moderate CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, phenobarbital, primidone); if unavoidable, consider increasing Ztalmy dose (up to max daily dose). May increase the risk of somnolence and sedation with concomitant other CNS depressants (eg, opioids, antidepressants, alcohol).
Adverse Reactions:
Somnolence, pyrexia, upper respiratory tract infection, salivary hypersecretion, seasonal allergy, sedation, bronchitis, influenza, gait disturbance, nasal congestion.
Generic Drug Availability:
NO
How Supplied:
Oral susp (135mL)—1, 5
